Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera) on Glycemic Control in Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents

NCT00134147 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00134147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00134147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A One Year, Open-Label Outpatient, Parallel Group Trial Assessing the Impact of the Availability of Inhaled Insulin (Exubera) on Glycemic Control in Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled on a Minimum of Two Oral Anti Diabetic Agents
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2005
Completion date
May 31, 2007
Enrollment
1,100
Sites
121

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus